Skip to main content

Retail & consumer

Mothercare PLC MTC View profile

SMALL-CAP MOVERS: Mothercare clings on, Ethernity cashes in and AIM dives for the foxholes

Once a staple of the high street, Mothercare's future hangs in the balance, and has done so for several months.

The shares rose 44% this week, including 11% on Friday, the day of its interim results.

Yet the figures painted a bleak picture, which suggests the mark-up is grounded more in hope than expectation.

We already knew a Middle East franchisee, responsible for more than a quarter of group turnover, planned to shut up shop.

In the results update chairman Clive Whiley said the planned closures had "seriously undermined the group's core objectives".

Mothercare has enough resources to trade for a number of months.

Whiley said the priority now is to conclude a strategic review of all business and pension scheme options before the year-end.

Turning to the wider market, the AIM All-Share fell victim to a risk-off flight to safety unrelated to the prospects for the UK's growth stocks. Put simply, the tech sell-off on Wall Street and in Asia has sent investors racing for their foxholes.

A beacon in the gloom was Ethernity Networks, up 195% after the developer of networking and security technology licensed its patents for a one-off $1.36 million. The buyer is a patent aggregator acting for a group of systems and semiconductor vendors.

The deal covers all seven of Ethernity's issued US patents. It is non-exclusive, so Ethernity keeps ownership and can sell licences to others.

The fee lands within ten business days. After withholding tax and costs, Ethernity expects to bank about $917,000. More deals could follow, though the company says there is no certainty. It will also keep reviewing its strategic options.

Sticking with the winners, Tavistock Investments jumped 91% after the wealth management group agreed an option deal to sell its private client arm to Atomos.

For £100,000, Atomos now has the exclusive right to buy Tavistock Group Holdings, which owns Tavistock Private Client, for up to a further £27.4 million.

Of that, £18.4 million is due on completion. It previously paid £1.5 million for exclusivity. Atomos has until 31 January to decide.

Surgical Innovations Group was up 38% after an investor lifted his stake to 4.72% in the medical devices group. Gordon Dow, through Lawshares Nominees, held 44 million shares by 16 November, up from 30.5 million (3.27%) on 6 November. That is a further 13.5 million shares in ten days. His first filing, on 10 November, reported no previous position.

Now, onto the week's losers. CT Automotive was down 56% after the maker of car interior components slashed its profit guidance.

Profit for 2026 is now expected to be about $300,000, against the $4.9 million to $9.4 million forecast in September. Revenue should reach $121 million, short of market expectations of $126.8 million.

The problems centre on its Mexican plant, which is responsible for about 40% of annualised revenue.

A new production system found $1 million of overstated inventory and a further $1 million of wrong margin assumptions, while cash constraints hit efficiency. Net debt was $16.5 million at the end of October.

Thruvision fell 33% after the developer of walk-through security technology warned of material uncertainty over its ability to continue as a going concern. The company plans to raise short-term debt to support working capital, but the funding is not yet committed.

Pulsar Group was down 29% after the audience intelligence software group secured a £5.5 million loan arranged by its largest shareholder, Kestrel, because an equity raise drew too little interest.

The loan runs for three years at 12.5% interest and ranks behind the group's HSBC debt. Lenders also get warrants over 33 million shares at 20p, which would dilute shareholders by about 24% if exercised.

Finally, broker Cavendish this week restated its 26p price target for IXICO, double the current share price.

It comes after a run of announcements from the medical imaging and AI analytics group.

On Thursday, it released a new version of its IXI Platform, which is easier to scale and to connect to partners' systems. That supports its plan to license technology for high-margin, recurring revenue.

Two new collaborations add a Parkinson's disease algorithm validated by the US Food and Drug Administration and more PET scan analysis for Alzheimer's.

It has also built an AI tool that detects about 90% of cerebral microbleeds on MRI scans, a key safety signal in Alzheimer's drug trials.

Cavendish says the updates show clear progress on its contract research and TechBio strategies, and should help it expand further into Alzheimer's and Parkinson's drug trials.

The shares, up 7% this week, have advanced 57% in the last month.